- Email: [email protected]
Addendum to “Photosensitizer delivery for photodynamic therapy of choroidal neovascularization”
Advanced Drug Delivery Reviews 53 (2001) 131 www.elsevier.com / locate / drugdeliv
Addendum
Addendum to ‘‘Photosensitizer delivery for photodynamic therapy of choroidal neovascularization’’ [Adv. Drug Deliv. Rev. 52 (2001) 63–78] q Reem Z. Renno (MD), Joan W. Miller (MD)* Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA
Verteporfin PDT Clinical Studies In describing the verteporfin clinical studies, we commented that no benefit was seen for eyes with occult CNV with no classic component. This statement was based on the results at 12 months of follow-up in the Verteporfin in PDT (VIP) Study. However, data at 24 months of follow-up showed a benefit to treatment, particularly for eyes with smaller lesions and worse visual acuity.
q
PII of the original article: S0169-409X(01)00195-8 *Corresponding author. Tel.: 1 1-617-573-3915; fax: 1 1-617-573-3698. E-mail address: [email protected] (J.W. Miller).
0169-409X / 01 / $ – see front matter 2001 Elsevier Science B.V. All rights reserved. PII: S0169-409X( 01 )00238-1
Addendum
Addendum to ‘‘Photosensitizer delivery for photodynamic therapy of choroidal neovascularization’’ [Adv. Drug Deliv. Rev. 52 (2001) 63–78] q Reem Z. Renno (MD), Joan W. Miller (MD)* Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA
Verteporfin PDT Clinical Studies In describing the verteporfin clinical studies, we commented that no benefit was seen for eyes with occult CNV with no classic component. This statement was based on the results at 12 months of follow-up in the Verteporfin in PDT (VIP) Study. However, data at 24 months of follow-up showed a benefit to treatment, particularly for eyes with smaller lesions and worse visual acuity.
q
PII of the original article: S0169-409X(01)00195-8 *Corresponding author. Tel.: 1 1-617-573-3915; fax: 1 1-617-573-3698. E-mail address: [email protected] (J.W. Miller).
0169-409X / 01 / $ – see front matter 2001 Elsevier Science B.V. All rights reserved. PII: S0169-409X( 01 )00238-1